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ABSTRACT 
Nodular goiter with autoimmune thyroiditis is one of the most important problems of modern endocrinology, with inadequately studied 
etiological and pathogenic mechanisms of development. It is characterized by the lack of objective and reliable diagnostic methods, 
effective treatment methods, uncertain therapy or indications for the choice of treatment methods. A total we have examined 125 patients 
who were operated for a nodular endemic goiter with autoimmune thyroiditis. Investigated the activity of proliferation and apoptosis of 
thyrocytes in the thyroid tissue of patients of nodular goiter with autoimmune thyroiditis considering the polymorphism of the bcl-2 
(rs17759659), ctla-4 (rs231775), apo-1/fas (rs2234767) genes. The expression/density markers - Fas/ FasL, Bcl-2, p53 and Ki-67 on the 
thyrocytes in the lymphoid infiltration and destruction areas, as well as in normal thyroid tissue (as a control) were studied. The number 
of immunoreactive cells, which expressed the above-mentioned regulating apoptosis and proliferation markers in NGAIT patients, 
depending on the genes polymorphism BCL-2 (rs17759659), CTLA-4 (rs231775) and APO-1/Fas (rs2234767) were counted. It was 
found that in NGAIT patients a few links of programmable thyroid cell killing of Fas-induced apoptosis were activated, and associated 
with the polymorphic cite of BCL-2 (rs17759659) gene and almost 6 times weaker with CTLA-4 (rs231775) gene, through enhanced 
expression of Fas and Fas L on the cells surface in lymphoid infiltration and destruction areas (stronger in GG genotype carriers of BCL-
2 gene). 
Keywords: nodular endemic goiter; autoimmune thyroiditis; apoptosis; proliferation; genes polymorphism. 
Abbreviations: NGAIT – nodular goiter with autoimmune thyroiditis; TG – thyroid gland; TPOAB – thyroperoxidase antibodies, TGAB 
– thyroglobulin antibodies. 
 
1. INTRODUCTION 
 One of the mechanisms of malignant transformation and 
progression is cell cycle dysregulation with apoptosis inhibition 
and activation of proliferation. Protein Ki-67, whose antibodies 
recognize DNA-related nuclear protein present in the nuclei of 
cells in 01-, 8-, 02- and M-phases and absent in the 00-phase, is a 
prospective intracellular marker of proliferation [1-6].  Protein p53 
is a diagnostically significant tumor marker being a product the 
gene suppressor of a tumor p53 is expressed in all cells, activated 
by a damage to the genetic apparatus, as well as by the stimuli that 
could lead to such damage, or that serve as a signal of an 
unfavorable condition of cells (stress). Its activation results in the 
cell cycle arrest, DNA replication, and excessive stress signal in 
apoptosis [7-11]. The function of anti-apoptotic protein p53 is to 
remove the cells that are potentially oncogenic out of the pool. In 
almost 50% of cases of human cancers, the loss of protein p53 
function is diagnosed [10-18].  
Cell death is mediated through the interaction of the surface 
cellular receptors Fas / Fas ligand, or CD95L (type ІІ of the 
transmembrane protein belonging to the family of tumor necrosis 
factor alpha (TNF), which is expressed on cytotoxic T 
lymphocytes) and gets activated through the apoptosis caspase 
trigger mechanism [19-20]. This is an important link to the 
pathological process to maintain the homeostasis of immune cells 
and immune defenses of the body. Using the Fas / FasL system, 
apoptosis is also an important means to destroy the cytotoxic T 
cells. [20-23].   
 Assessing the markers which regulate apoptosis (protein 
р53, Bcl-2, Fas-system) and proliferation (protein Ki-67), as well 
as their relationship with polymorphism of genes associated with 
apoptosis, the role of autoimmune reactions in this process has not 
been studied well enough and requires further research.  
 Therefore, the purpose of this phase of our work is the 
analysis of apoptosis and proliferation indices (expression/density 
Volume 10, Issue 2, 2020, 5201 - 5208 ISSN 2069-5837 
Open Access Journal 
Received: 09.10.2019 / Revised: 20.01.2020 / Accepted: 25.01.2020 / Published on-line: 03.02.2020 
  Original Research Article 
Biointerface Research in Applied Chemistry 
www.BiointerfaceResearch.com 
https://doi.org/10.33263/BRIAC102.201208 
Michael I. Sheremet, Larysa P. Sydorchuk, Viktor O. Shidlovskyi, Volodimir I. Desiateryk, Anatoliy E. Kovalenko, Stanislav I. 
Shevchenko, Serhiy M. Zavgorodnyi, Nina P. Tkachuk, Antonina A. Piddubna 
Page | 5202  
of markers Fas / FasL, Bcl-2, p53 and Ki-67 on thyrocytes in the 
areas of lymphoid infiltration and destruction of thyrocytes as well 
as in morphologically unaltered areas of the thyroid tissue (as a 
control), and counting the number of immunoreactive cells that 
express the above mentioned markers, which regulate apoptosis 
and proliferation for AIT and TA, using immunohistochemical 
method considering polymorphism of BCL-2 (rs17759659), 
CTLA-4 (rs231775) and APO-1/Fas (rs2234767) genes. 
2. MATERIALS AND METHODS 
 During 2014-2019 we have examined 125 women 
complaining about discomfort in the neck. We evaluated the 
hormonal status (TSH, free T4 and free T3) ratio of antibodies to 
thyroglobulin (ABTG) and to thyroid peroxidase (AT- TPD), the 
volume and structure of the thyroid gland (TG) according to 
ultrasound. 50 of them were diagnosed with AIT (I-group, the 
main). Indications for surgery in this group of patients were: 
enlargement of the thyroid gland with symptoms of compression 
and narrowing of the trachea and esophagus; the nodes 
compressed on the neck organs; progressive growth of goiter, 
despite ongoing for 1-1.5 years conservative therapy; suspected 
malignant degeneration, based on FNAB findings. The final 
confirmation of morphologically unchanged tissue was obtained 
after histological conclusion. The study did not involve patients 
with hyperthyroidism, clinical hypothyroidism, hypertension and 
cardiovascular diseases, severe somatic pathology and those after 
the menopause onset. All patients underwent surgery. The extent 
of the surgery - from hemithyroidectomy to thyroidectomy.  
 After the intervention, the thyroid tissue was removed for 
immunohistochemical studies no later than 30 minutes after the 
operation. In patients with TA we also took unchanged tissue of 
the lobe of the TG and adenomatous tissue for the study. In 
patients with AIT the tissue from both lobes and from the isthmus 
was taken. Pieces of tissue weighing 100-300 mg were transported 
on ice to a laboratory and immediately cut into 4-6 pieces 
weighing an average 50-70 mg each. After the partition they were 
closed in a special plastic container and stored at -70 ° C until 
basic research was performed. All patients’ surgical material 
(tissue) was used to prepare cell suspension by painting thyrocytes 
with monoclonal antibodies (MAbs) to membrane receptors and 
intracellular proteins.  
 
Figure 1. Histogram of the thyroid tissue heterogeneous suspension with 
limited gating area (A). 
 
 We used ICA to estimate the parameters of apoptosis and 
proliferation produced by the firm «CALTAG» (Austria) - Bcl-2-
Fits, Fas-PE-Cy5, FasL-PE-Cy5 and p53-Fits and Ki-67-PE of the 
firm «DAKO» (USA). The density of expression of the membrane 
(intracellular) receptors (proteins) was evaluated in standard units 
(St. Un.) according to the average intensity of fluorescence light 
(MFI), which was proportional to the channel number, measured 
in logarithmic mode. When counting cells we evaluated 
proliferation and apoptosis indices in research areas, using gating 
(Fig. 1), in which we determined the window, where the cells 
under 25 microns passed.  
 We determined the number of cells and their density with 
markers distributed on the surface of cells, Fas, FasL and 
intracellular proliferation marker Ki-67 and apoptosis bcl-2, p53. 
Phenotyping was performed on flow cytofluorimeter counting 
100.000 events in the sample and calculating the relative number 
of cells and measuring the density of expression of receptors 
(proteins) in cells or groups of cells. 
  
Figure 2. CTLA4 gene polymorphism (rs 231775) alleles discrimination. 
 
 
Figure 3. BCL-2 gene polymorphism (17759659) alleles discrimination. 
 
 Digital data (histograms) as files (LMD) were analyzed by 
means of a special analytical program CXP ver.2.2 obtaining the 
results of the research. We also studied small groups of cells 
formed with possible combinations: p53 / Ki-67, p53 / Fas, bcl-2 / 
Ki-67, bcl-2 / Fas, Fas / Ki-67, p53 / FasL, Fas / FasL, Bcl- 2 / 
FasL. 
 The processes of proliferation and apoptosis in thyroid 
tissue were studied in patients with NGAIT and compared with 
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norm for the region. It was identified in the comparison group in 
the study of thyroid tissue taken from 36 residents of Chernivtsi 
region, who died during an accident and accidents. The material 
was received at the Chernivtsi Pathological and Anatomical 
Bureau in accordance with the agreement on joint research 
between the Higher Medical University of Ukraine “Bukovyna 




Figure 4. FAS gene polymorphism (rs 2234767) alleles discrimination. 
Genetic studies performed in the laboratory of genetics at the State 
University of Medicine and Pharmacy "Nicolae Testemițanu", 
Chisinau (Republic of Moldova). DNA was extracted from whole 
venous blood lymphocytes. Venous blood was stored in test tubes, 
stabilized with K2-EDTA. Isolation and purification of DNA from 
the material obtained were performed according to methodological 
guidance of Thermo Scientific GeneJET Genomic DNA 
Purification kit (#K0721, Thermo Fisher Scientific).  
Quantitative Real-Time PCR (RT-PCR). 
 Polymerase chain reaction (PCR) was performed in real-
time (RT-PCR) using Taq-DNA polymerase and specific primers 
on QuantStudio 6 equipment, Applied Biosystems (USA), which 
allowed us to obtain amplicons to determine their number in "real 
time" and reduce the likelihood of diagnostic error. Analysis of the 
data was performed using the Quant Studio Real Time Software 
(Fig. 2-4). 
Statistical Analysis 
Statistical analysis was performed using Statistica 7.0 (StatSoft 
Inc, USA) software. Nominal data presented in the form of 
quantitative and percentages. For the genotypes distribution 
comparison used Pearson's criterion (2). Analysis of qualitative 
data (categorical variables), risk of thyroid pathology development 
was assessed using a binary logistic regression model using the 
relative risk (RelR), risk ratio (RR) and odds ratio (OR) with 95% 
confidence interval [95% CI], chi-square test (χ2) (df=1). The 
difference was considered reliable at p<0.05. 
3. RESULTS  
 Cell number and density of the receptors with markers, 
distributed on the surface of Fas, FasL cells and intracellular 
proliferation markers Ki-67 and apoptosis of Bcl-2, p53 
considering the polymorphic variants of Bcl-2 (rs17759659) gene 
are shown in tables 2. The number of immunoreactive cells 
expressing transmembrane protein Fas on the surface is reliably 
higher in the homozygous carriers of minor G-allele of the BCL-2 
gene than in the owners of the main A-allele (AA- and AG-
genotypes) by 18.54% (рАА=0.043) and 36.18% (рАG=0.018). As 
for other indices (the number of cells with receptors to Fas L and 
intracellular markers of apoptosis - p53, Bcl-2 and proliferation – 
Ki-67 and the density of these markers both on the surface and 
inside the cells) considering the polymorphism of the BCL-2 
(rs17759659) gene, they were not determined. While comparing 
with the reference values of the control group, in general, we 
established in the patients with thyroid pathology a reliably higher 
number of cells with receptors to Fas, Fas L, Bcl-2 and Кi-67 
(р≤0.055-0.001). On the other hand, the density of receptors Fas 
and Fas L on the thyrocyte surface was reliably lower than in the 
control group (p<0.05), which did not depend on the polymorphic 
variants of the BCL-2 gene. However, the indices of Ki-67 
proliferation and apoptosis due to the proteins-oncosuppressors 
Bcl-2 and p53 in patients with thyroid pathology, with a density of 
corresponding proteins within the cell, were reliably higher than 
those in the control group (p<0.05).  
 Univariate analysis of variance confirmed the association 
of the promoter of BCL-2 (rs17759659) gene with the number of 
cells expressing Bcl-2 (F=7.25, p<0.001), р53 (F=10.58, p<0.001), 
Fas (F=25.33, p<0.001), Fas L (F=7.18, p=0.001), Кi-67 (F=3.60. 
p=0.03) and with the density of the receptors Fas L (F=9.74, 
p<0.001) as well as the protein proliferation marker  Кi-67 
(F=13.20. p<0.001) (table 2). 
 Receptor density and the number of immunoreactive cells 
of apoptosis and proliferation markers in the thyroid tissue 
considering the polymorphic variants of CTLA-4 (rs231775) gene 
are shown in table 3. The density of intracellular protein that 
regulates the process of Ki-67 proliferation prevailed in the 
carriers of minor allele G (AG-, GG-genotypes) of the CTLA-4 
gene over-AA genotype by 10% (p=0.033) and by11.5% 
(p=0.046). For the rest of the markers, there were no reliable 
differences depending on the polymorphism of the CTLA-4 
(rs231775) gene. The number of cells with receptors to Fas, Fas L 
and Ki-67, as well as the density of intracellular anti-apoptotic 
proteins p53 and Bcl-2 and proliferation of Ki-67 reliably 
prevailed the reference values of the control group (p≤0.048-
0.001). 
 Univariate analysis of variance confirmed the association 
of the promoter of CTLA-4 (rs231775) gene with the number of 
cells expressing p53 (F=8.35, p<0.001), Fas (F=4.23, p=0.017), 
Fas L (F=5.61, p=0.005), Ki-67 (F=3.72, p=0.027) and the density 
of receptors Fas (F=17.17, p=0.001) of anti-apoptotic Bcl-2 
(F=3.09, p=0.049) and p53 (F=18.18, p<0.001) and the 
proliferation marker of Ki-67 protein (F=56.26, p<0.001) (table 4). 
The receptor density indices and the number of the apoptosis and 
proliferation cells-markers in the thyroid tissue do not depend 
directly on the polymorphic variants of the APO-1/Fas 
(rs2234767) gene (table 4). The number of the cells with receptors 
to Fas, Fas L and Кi-67, as well as the density of intracellular anti-
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apoptotic p53 and Bcl-2 proteins and proliferation of Кi-67 were 
reliably higher than in the control group (р≤0.019-0.001). 
Univariate analysis of variance (table 4) confirmed the association 
of promoter of the APO-1 / Fas (rs2234767) gene with the number 
of cells expressing Fas L (F=8.37, p=0.005) and the density of 
receptors Fas (F=115.28, p<0.001) and intracellular protein p53 
(F=10.62, p=0.001). 
 
Table 2. Density of the receptors and the number of the cells in the markers of apoptosis and proliferation in the thyroid tissue according to 
the polymorphic variants of the BCL-2 (rs17759659) gene. 
Indices Control, n=36 Gene BCL-2 genotypes in patients 
АА, n=10 AG, n=110 GG, n=5 
Fas cells, % 0.79±0.04 23.28±2.30 
p<0.001  








7.38±1.12 p<0.001 6.45±0.95 p<0.001 
Fas L cells, % 3.85±0.16 11.93±1.71 
p=0.003 
10.57±1.34 р=0.002 12.14±1.45 p=0.002 




8.29±0.64 p=0.009 7.34±0.39 p=0.005 
Total number of р53 
cells, % 
64.14±1.89 67.79±1.27 59.47±7.0 68.02±1.52 
Density of р53 
protein, (total), s.u. 
1.41±0.05 3.46±0.93 
p=0.035 
3.86±0.58 р=0.004 3.60±0.94 p=0.028 
Кi-67 cells,% 1.16±0.05 4.26±0.53 
p=0.001 





2.11±0.22 р=0.005 1.88±0.24 p=0.012 
Вс1-2 cells,% 73.05±1.35 80.66±2.99 
p=0.027 
78.22±2.44 p=0.055 81.23±3.47 p=0.037 




6.62±1.07 p=0.013 7.40±1.49 p=0.026 
Notes: 1.– reliability of index differences compared to those in the control group; рАА – reliability of index differences with carriers of АА-
genotype; рAG – reliability of index differences with carriers of AG-genotype. 
 
Table 3. The density of receptors and the number of cells in the markers of apoptosis and proliferation in the thyroid tissue according to the 
polymorphic variants of the CTLA-4 (rs231775) gene. 
Indices Control, n=36 Genotypes of the CTLA-4 gene in patients 
АА, n=59 AG, n=62 GG, n=4 
Fas cells, % 0.79±0.04 18.62±4.20 
p<0.001  
18.90±4.02 p<0.001 12.81±1.25 
p<0.001 




7.10±1.80 p=0.007 10.12±1.05 p=0.01 
Fas L cells, % 3.85±0.16 10.64±1.40 
p=0.003 
10.81±1.26 р=0.002 8.52±1.18 p=0.006 




8.15±0.57 p=0.004 8.19±0.47 p=0.005 
Total number of р53 
cells, % 
64.14±1.89 61.46±4.39 58.39±5.26 65.03±2.90 




4.01±0.35 р<0.001 3.03±0.56 p=0.008 
Кi-67cells,% 1.16±0.05 3.71±0.62 
p=0.005 
3.89±0.63 p=0.004 3.09±0.77 p=0.019 
Density of Кі-67protein, 
s.u. 
1.20±0.07 2.0±0.08 p<0.001 2.20±0.11  
р<0.001 рAA=0.033  
2.23±0.08 р<0.001 
рAA=0.046 
Вс1-2 cells,% 73.05±1.35 78.49±3.24 78.40±2.36 77.21±4.82 




6.79±0.64 p=0.003 6.08±1.0 p=0.037 
Notes: 1. TG – Thyroid gland; 2. р – reliability of differences between the indices as compared to those in the control group; рАА – reliability 
of differences between the indices as compared to those in the carriers of the АА-genotype; рAG – reliability of differences between the indices 
as compared to those in the carriers of the AG-genotype. 
 
Based on the frequency of increasing (moderate, 
significant) or decreasing the number of cells and the density of 
receptors expressing the markers of apoptosis and proliferation 
considering polymorphism of the APO-1 / Fas (rs2234767) gene 
we established the trends similar to those described in tables 3.24 
and 3.26 with the frequency difference 3.08 and 3.60 fold 
(р<0.001), without reliable differences according to polymorphic 
variants of the Fas (rs2234767) gene.  
 Analysis of markers of apoptosis and proliferation, as the 
risk factors of the studied thyroid pathology showed that high 
compensatory increase in cells in the biopsy expressing Fas, Fas L 
and Ki-67 and a moderate increase in cells with Bcl-2 with 
significant decrease in the density of receptors on the cell surface 
of Fas and Fas L and an increase in the density within the cell of 
the anti-apoptotic Bcl-2 protein increases the risk of thyroid 
pathology (AIT and TA) by 2.79 and 9 times in the carriers of 
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AG- and, in particular, AA-genotypes of the BCL-2 (rs17759659) 
gene, respectively (OR=7.80 and OR=81,0; p<0.001) (table 5). On 
the other hand, a significant increase of the proliferation Ki-67 
protein density by reducing the number of cells containing p53 
oncosuppression protein (significant, >50 percentiles) and a 
moderate reduction of Bcl-2 protein (≤50 percentiles) is a 
protection factor and make the chances of AIT and TA occurrence 
the lowest in the surveyed population of the Northern Bukovyna 
residents regardless of BCL-2 gene genotypes (OR=0.01; 95% CI 
OR: 0.001-0.23 for AA-genotype and OR=0.13; 95% CI OR: 
0.07-0.23 for AG-genotype, respectively, p<0.001). 
 
Table 4. The density of receptors and the number of cells in the markers of apoptosis and proliferation in the thyroid tissue according to the 
polymorphic variants of the APO-1/Fas (rs2234767) gene. 
Indices Control, n=36 Genotypes of the APO-1/Fas gene in patients 
AG, n=23 GG, n=102 
Fas cells, % 0.79±0.04 17.70±4.35 p<0.001 18.75±4.25 
p<0.001 
Density of  Fas receptors, s.u. 13.82±0.40 7.10±1.80 р=0.007 10.12±1.05 р=0.009 
Fas L cells, % 3.85±0.16 7.95±1.17 р=0.008 7.25±1.02 p=0.009 
Density of Fas L receptors, s.u. 11.13±0.85 10.30±1.42 10.73±1.33 
Total number of р53 cells, % 64.14±1.89 60.83±4.59 60.09±4.83 
Density of р53 protein, (total), s.u. 1.41±0.05 3.58±0.41 р=0.002 3.87±0.38 p=0.001 
Number of Кi-67cells, % 1.16±0.05 3.72±0.66 p=0.006 3.79±0.63 p=0.004 
Density of Кі-67protein, s.u. 1.20±0.07 2.02±0.20  
р=0.006  
2.09±0.21 p=0.005 
Number of Вс1-2 cells, % 73.05±1.35 78.34±2.63 78.42±1.81 p=0.02 
Density of Вс1-2 protein, s.u. 3.86±0.16 6.49±0.63 p=0.005 6.70±0.58 p=0.003 
Notes: 1.– reliability of differences between the indices as compared to those in the control group; рAG – reliability of differences between the 
indices as compared to those in the carriers of the AG-genotype.   
 
Table 5. Polymorphic variants of the BCL-2 (rs17759659) gene as the risk factors of apoptosis and proliferation in the thyroid tissue. 
Indices / Genotypes of the BCL-
2 gene 
RelR OR 95%СІ  RR 95%СІ OR р 
Fas, Fas L and Кi-
67cells, % (significant 
increase) 
АА 9.0 81.0 1.38-58.44 4.36-1504.5 <0.001 
AG 2.79 7.80 2.0-3.89 4.28-14.21 <0.001 
Density of Fas and Fas L 
receptors, s.u. 
(sifnificant increase) 
АА 9.0 81.0 1.38-58.44 4.36-1504.5 <0.001 
AG 2.79 7.80 2.0-3.89 4.28-14.21 <0.001 
Density of Кі-67protein, 
s.u. (significant increase) 
АА 0.11 0.01 0.02-0.72 0.001-0.23 <0.001 
AG 0.36 0.13 0.26-0.50 0.07-0.23 <0.001 
Total number of 
р53cells, % ( (significant 
increase) 
АА 0.11 0.01 0.02-0.72 0.001-0.23 <0.001 
AG 0.36 0.13 0.26-0.50 0.07-0.23 <0.001 
Вс1-2 cells, % (moderate 
decrease) 
АА 0.11 0.01 0.02-0.72 0.001-0.23 <0.001 
AG 0.36 0.13 0.26-0.50 0.07-0.23 <0.001 
Вс1-2 cells, % (moderate 
increase) 
АА 9.0 81.0 1.38-58.44 4.36-1504.5 <0.001 
AG 2.79 7.80 2.0-3.89 4.28-14.21 <0.001 
Density of Вс1-2 protein, 
s.u. (significant increase) 
АА 9.0 81.0 1.38-58.44 4.36-1504.5 <0.001 
AG 2.79 7.80 2.0-3.89 4.28-14.21 <0.001 
Note. RelR - Relative Risk; OR -Odds Ratio; 95%CІ RR, OR – 95% confidence interval of Risk Ratio, Odds Ratio 
  
We have found that the analyzed markers of thyroid 
tissue apoptosis and proliferation (high content of cells in the 
biopsy expressing Fas, Fas L, Ki-67, Bcl-2, a significant decrease 
of the Fas and Fas L receptors density on the cell surface and a 
high increase of the Bcl-2 protein density increase the risk of 
thyroid pathology (AIT and TA) by 3.92 times in AA genotype 
carriers of the CTLA-4 gene (OR=15,34; 95% CI OR: 6,26-37,60; 
p<0.001) (table 6) and by 2.44 times in AG-genotype patients of 
the CTLA-4 gene (OR=5,98; 95% CI OR: 2,75-12,98; p<0.001) 
and by 3,08 times in homozygous wild G-allele carriers of the 
APO-1 / Fas (rs2234767) gene (table 7) and by 3,60 times in AG-
genotype patients of the above-mentioned gene (OR=9,49; 95% 
CI OR: 5,01-17,96 and OR=12,96; 95% CI OR: 3,19-52,62; 
p<0.001), respectively. 
The factors which decrease the likelihood of NGAIT 
occurrence in the examined patients regardless of the genotypes of 
the CTLA-4 (rs231775) and APO-1/Fas (rs2234767) genes are 
(tables 6, 7): high compensatory increase in the Ki-67 protein 
proliferation density and reduction of the cells containing the 
proteins p53 or Bcl-2 (OR=0.07-0.17; 95% CI OR: 0.03-0.36; 
p<0.001, and OR=0.08-0.11; 95% CI OR: 0.02-0.31; p<0.001, 
respectively). 
Thus, the NGAIT patients with compensatory increased 
number of immunoreactive cells expressing Ki-67 and this protein 
density, the most strongly associated with the CTLA-4 gene 
polymorphic site (F=56,26; p<0.001) and almost 4 times less with 
the BCL-2 gene promoter (F=13,20; p<0.001) and is reliably 
higher only in the minor G-allele carriers of CTLA-4 gene by 10% 
(p=0.033) and 11.5% (p=0.046), indicating the maintenance of the 
stored follicular thyroid epithelium regeneration, especially in G-
allele carriers. 
 High concentrations of cells expressing Fas, Fas L, Ki-
67, Bcl-2 (>50 percentiles) in thyroid biopsies, accompanied by 
Fas and Fas L receptors density reduction on the cell surface (<50 
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percentiles) and high protein Bcl-2 density growth, increase the 
NGAIT risk in observed population 2.79 in AG- and particular 
AA-genotype carriers of BCL-2 gene (rs17759659) (OR=7,80 and 
OR=81,0; p<0.001, respectively); 2.44 times in the AG- and 
especially AA-genotypes carriers of the CTLA-4 gene (OR=15,34; 
95% CI OR: 6,26-37,60; p<0.001 and OR=5,98; 95% CI OR: 
2,75-12,98; p<0.001); by 3.08 times in the GG- and AG genotype 
patients of the Fas (rs2234767) gene (OR=9,49; 95% CI OR: 
5,01-17,96 and OR=12.96; 95% CI OR: 3,19-52,62; p<0.001), 
respectively. 
 Protection factors that reduce the NGAIT likelihood in 
the surveyed population of the Northern Bukovyna, regardless of 
the analyzed genes polimorpic variants, include compensatory 
increase the Ki-67 proliferation protein density in the thyrocyte 
(>50 percentiles) and reduction of the cells containing p53 or Bcl-
2 proteins (OR=0.01-0.17; 95% CI OR: 0.001-0.36; p<0.001 and 
OR=0.07-0.13; 95% CI OR: 0.02-0.31; p<0.001, respectively). 
 
Table 6. Polymorphic variants of the CTLA-4 (rs231775) gene as risk factors of apoptosis and proliferation in the thyroid tissue. 
Indices / genotypes of the CTLA-4 
gene 
RelR OR 95%СІ  RR 95%СІ OR р 
Number of Fas, Fas L і 
Кi-67 cells, % 
(sifnificant increase) 
АА 3.92 15.34 2.33-6.60 6.26-37.60 <0.001 
AG 2.44 5.98 1.61-3.72 2.75-12.98 <0.001 
Density of Fas and Fas L 
receptors, s.u. 
(significant decrease) 
АА 3.92 15.34 2.33-6.60 6.26-37.60 <0.001 
AG 2.44 5.98 1.61-3.72 2.75-12.98 <0.001 
Density of Кі-67protein, 
у.о. (significant increase 
АА 0.25 0.07 0.15-0.43 0.03-0.16 <0.001 
AG 0.41 0.17 0.27-0.62 0.08-0.36 <0.001 
Total number of р53 
cells, % (significant 
decrease) 
АА 0.25 0.07 0.15-0.43 0.03-0.16 <0.001 
AG 0.41 0.17 0.27-0.62 0.08-0.36 <0.001 
Number of Вс1-2 cells, 
% (moderate decrease) 
АА 0.25 0.07 0.15-0.43 0.03-0.16 <0.001 
AG 0.41 0.17 0.27-0.62 0.08-0.36 <0.001 
Number of Вс1-2 cells, 
% (moderate increae) 
АА 3.92 15.34 2.33-6.60 6.26-37.60 <0.001 
AG 2.44 5.98 1.61-3.72 2.75-12.98 <0.001 
Density of Вс1-2 protein, 
s.u. (significant increase) 
АА 3.92 15.34 2.33-6.60 6.26-37.60 <0.001 
AG 2.44 5.98 1.61-3.72 2.75-12.98 <0.001 
Note. RelR - Relative Risk; OR -Odds Ratio; 95%CІ RR, OR – 95% confidence interval of Risk Ratio, Odds Ratio 
 
Table 7. Polymorphic variants of the APO-1/Fas (rs2234767) gene as risk factors of apoptosis and proliferation in the thyroid tissue. 
Indices / genotypes of the APO-1/Fas 
gene 
RelR OR 95%СІ  RR 95%СІ OR р 
Number of  Fas, Fas L і 
Кi-67cells, % (significant 
increase) 
AG 3.60 12.96 1.61-8.05 3.19-52.62 <0.001 
GG 3.08 9.49 2.15-4.41 5.01-17.96 <0.001 
Density of Fas і Fas L 
receptors, s.u. 
(significant decrease) 
AG 3.60 12.96 1.61-8.05 3.19-52.62 <0.001 
GG 3.08 9.49 2.15-4.41 5.01-17.96 <0.001 
Density of Кі-67protein, 
s.u. (significant increase) 
AG 0.28 0.08 0.12-0.62 0.02-0.31 <0.001 
GG 0.32 0.11 0.23-0.46 0.06-0.20 <0.001 
Total number of р53 
cells, % (significant 
decrease) 
AG 0.28 0.08 0.12-0.62 0.02-0.31 <0.001 
GG 0.32 0.11 0.23-0.46 0.06-0.20 <0.001 
Number of Вс1-2 cells, 
% (moderate decrease) 
AG 0.28 0.08 0.12-0.62 0.02-0.31 <0.001 
GG 0.32 0.11 0.23-0.46 0.06-0.20 <0.001 
Number of  Вс1-2 cells, 
% (moderate decrease) 
AG 3.60 12.96 1.61-8.05 3.19-52.62 <0.001 
GG 3.08 9.49 2.15-4.41 5.01-17.96 <0.001 
Density of Вс1-2 protein, 
s.u. (significant increase) 
AG 3.60 12.96 1.61-8.05 3.19-52.62 <0.001 
GG 3.08 9.49 2.15-4.41 5.01-17.96 <0.001 
Note. RelR - Relative Risk; OR -Odds Ratio; 95%CІ RR, OR – 95% confidence interval of Risk Ratio, Odds Ratio 
 
4. CONCLUSIONS 
 Thus, patients with NGAIT activate several links of a 
programmed thyrocyte killing where  Fas-induced apoptosis 
prevails and is the most associated with the promoter of the  BCL-
2 (rs17759659) gene (F=25,33; p<0,001) and about 6 times less 
with the promoter of the CTLA-4 (rs231775) gene (F=4,23, 
p=0,017), due to the pronounced expression of Fas і Fas L on the 
cellular surface in the areas of the lymphoid infiltration and 
destruction of thyrocytes (more pronounced in the carriers of GG-
genotype of the BCL-2  gene– by18,54% (рАА=0,043) and 36,18% 
(рАG=0,018) respectively), which indicates the initiation of 
apoptosis external way through the caspase mechanism (effector 
caspases 8). 
 2. An increased expression of Bcl-2 in the thyroid 
lymphocytes of patients with AIT and TA is associated 
exclusively with the promoter region of the BCL-2 (rs17759659) 
gene according to the results of univariate analysis of variance (F 
= 7,25, p <0,001), without a clear dependence on certain 
polymorphic variants, with unreliable changes in the expression of 
p53 protein (it is also associated with the polymorphic site of 
BCL-2, F = 10,58; p <0,001), indicating a slight control of 
apoptosis (despite a compensatory increase in the density of  p53 
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inside the thyrocyte, which, although connected with the promoter 
regions of CTLA-4 (F = 18,18, p <0,001) and APO-1 / Fas (F = 
10,62, p = 0,0 01) genes, does not affect significantly (p> 0.05) the 
expression of this protein) with a possible extension of the cell 
survival time and insufficient removal from the pool of the cells 
that are potentially oncogenic, which supposedly can contribute to 
carcinogenesis.  
 The patients with NGAIT have compensatory increased 
number of immunoreactive cells expressing Ki-67 and the density 
of this protein, which is most strongly associated with 
polymorphic site of the CTLA-4 gene (F = 56,26; p <0,001) and 
almost 4 times less with the promoter of the BCL-2 gene (F = 
13,20; p <0,001) and is reliably higher only in the G-owners of 
minor allele gene CTLA-4 by 10% (p = 0.033) and 11.5% (p = 
0.046), indicating the maintaining of the stored follicular thyroid 
epithelium regeneration, especially in the carriers of this allele. 
 High concentrations of the cells expressing Fas, Fas L, Ki-
67, Bcl-2 (> 50 percentiles) in the thyroid biopsy, accompanied 
bya reduction of the density of Fas and Fas L receptors on the cell 
surface (<50 percentiles) and high growth of the protein Bcl- 2 
density increase the risk of NGAIT: by 2.79 and 9 times AG- 
media and, in particular, AA-genotype BCL-2 gene (rs17759659), 
respectively (OR = 7,80 and OR = 81,0; p <0.001); by 2.44 and 
3.92 times in the AG carriers and especially AA genotypes of the 
CTLA-4 gene (OR = 15,34; 95% CI OR: 6,26-37,60; p <0.001 and 
OR = 5,98 ; 95% CI OR: 2,75-12,98; p <0.001); by 3.08 and 3.60 
times in the homozygous owners of the main G-allele and the AG 
genotype of the APO-1 / Fas (rs2234767) gene (OR = 9,49; 95% 
CI OR: 5,01-17,96 and OR = 12.96; 95% CI OR: 3,19-52,62; p 
<0.001), respectively. 
 Protection factors that reduce the likelihood of NGAIT in 
the surveyed population of the Northern Bukovyna residents, 
regardless of genotypes of the analyzed genes, include 
compensatory increase in the density of proliferation protein in the 
Ki-67 thyrocyte (> 50 percentiles) and reduction of the cells 
containing p53 or Bcl- 2 proteins (OR = 0,01-0,17; 95% CI OR: 
0,001-0,36; p <0.001 and OR = 0,07-0,13; 95% CI OR: 0,02-0,31; 
p <0.001, respectively). 
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